Results 251 to 260 of about 28,689 (318)

UEG Week 2025 Oral Presentations

United European Gastroenterology Journal, Volume 13, Issue S8, Page S7-S188, October 2025.
wiley   +1 more source

Ruxolitinib and decitabine plus a busulfan-cyclophosphamide conditioning regimen for relapse prophylaxis in patients with high-risk acute myeloid leukemia or myelodysplastic syndromes. [PDF]

Front Immunol
Wei Y, Luan S, Wang L, Wang L, Li F, Jin X, Yang R, Qian K, Peng B, Tang J, Zhang H, Dou L, Liu D.   +12 more
europepmc   +1 more source

Targeting an IKBKE cytokine network impairs triple-negative breast cancer growth [PDF]

, 2014
Barbie, Thanh U, Ellis, Matthew J, et al,, Fleming, Timothy, Gillanders, William E, Herndon, John, Li, Shunqiang, Zhang, Xiuli   +7 more
core   +2 more sources

A Systematic Review of the Use of Janus Kinase Inhibitors in Large Vessel Vasculitis. [PDF]

Cureus
Chay T, Patel T, Dumaru N, Maddukuri S, Haddad RR, Battula NS, Mohammed L.   +6 more
europepmc   +1 more source

Increased Rate of Anemia and Discontinuation in Older Patients with Myelofibrosis Treated with Ruxolitinib. [PDF]

J Clin Med
Laganà A, Scalzulli E, Carmosino I, Bisegna ML, Ielo C, Andriola C, Martelli M, Breccia M.   +7 more
europepmc   +1 more source

Ruxolitinib and Hepatitis-B Virus Reactivation: A Clinical Concern Requiring Prophylactic Management. [PDF]

Pak J Med Sci
Park JE, Yang J, Han S.
europepmc   +1 more source

Synergistic anticancer effects of ruxolitinib and calcitriol in estrogen receptor‑positive, human epidermal growth factor receptor 2‑positive breast cancer cells

, 2018
Seung Taek Lim, Ye Won Jeon, Hongki Gwak, Se Young Kim, Young Jin Suh   +4 more
openalex   +2 more sources

Ruxolitinib Modulates P-Glycoprotein Function, Delays T Cell Activation, and Impairs CCL19 Chemokine-Directed Migration in Human Cytotoxic T Lymphocytes. [PDF]

Int J Mol Sci
Biwott K, Lkhamkhuu A, Ghaffar N, Papp AB, Tarban N, Goda K, Bacso Z.   +6 more
europepmc   +1 more source

A Phase 2 Study of the Safety and Efficacy of INCB050465, a Selective PI3Kδ Inhibitor, in Combination with Ruxolitinib in Patients with Myelofibrosis

, 2018
Naval Daver, Marina Kremyanskaya, Casey L. O’Connell, Kim‐Hien Dao, Stephen T. Oh, Aaron T. Gerds, Srđan Verstovšek, Sue Erickson-Viitanen, Feng Zhou, Albert Assad, Abdulraheem Yacoub   +10 more
openalex   +1 more source

Efficacy and safety of ruxolitinib combined with steroids for first-line treatment of acute graft-versus-host disease after hematopoietic stem cell transplantation: a single-center, real-world experience. [PDF]

Front Immunol
Yang Y, Huo Y, Zhou D, Kang Z, Huang Y, Wang Y, Fan G, Ma L, Yan J.   +8 more
europepmc   +1 more source